CervoMed (CRVO) to Release Earnings on Tuesday

CervoMed (NASDAQ:CRVO) is expected to be announcing its Q3 2025 results before the market opens on Tuesday, November 11th. Analysts expect the company to announce earnings of ($0.68) per share and revenue of $1.4330 million for the quarter. Parties can check the company’s upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Wednesday, November 12, 2025 at 9:30 AM ET.

CervoMed (NASDAQ:CRVO) last posted its earnings results on Friday, August 8th. The company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.13). CervoMed had a negative return on equity of 59.15% and a negative net margin of 290.72%.The firm had revenue of $1.76 million during the quarter, compared to analysts’ expectations of $1.45 million. On average, analysts expect CervoMed to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CervoMed Stock Performance

CRVO stock traded up $0.31 during midday trading on Tuesday, reaching $7.33. 62,456 shares of the company traded hands, compared to its average volume of 1,556,971. CervoMed has a 52-week low of $1.80 and a 52-week high of $16.94. The business has a 50 day moving average of $8.36 and a 200-day moving average of $8.27. The firm has a market capitalization of $67.78 million, a price-to-earnings ratio of -2.81 and a beta of -0.84.

Wall Street Analysts Forecast Growth

A number of research firms have recently commented on CRVO. D. Boral Capital reaffirmed a “buy” rating and set a $31.00 target price on shares of CervoMed in a research note on Tuesday. Weiss Ratings reissued a “sell (d-)” rating on shares of CervoMed in a research note on Wednesday, October 8th. Chardan Capital reissued a “buy” rating and issued a $15.00 price objective on shares of CervoMed in a research note on Monday, August 11th. HC Wainwright reaffirmed a “neutral” rating and set a $11.00 target price on shares of CervoMed in a research report on Monday, September 8th. Finally, Zacks Research cut CervoMed from a “hold” rating to a “strong sell” rating in a research report on Monday, October 13th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and three have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $19.86.

Hedge Funds Weigh In On CervoMed

A number of institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of CervoMed during the 2nd quarter worth approximately $414,000. AQR Capital Management LLC acquired a new position in shares of CervoMed during the 1st quarter worth approximately $227,000. Marshall Wace LLP acquired a new position in shares of CervoMed during the 2nd quarter worth approximately $76,000. Finally, Rhumbline Advisers boosted its holdings in shares of CervoMed by 35.5% during the 1st quarter. Rhumbline Advisers now owns 5,830 shares of the company’s stock worth $53,000 after purchasing an additional 1,526 shares during the last quarter. Hedge funds and other institutional investors own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.